Important Changes to the Guerbet Board of Directors

On March 20, 2024, Guerbet, a globally recognized player in the contrast media and medical imaging solutions industry, formalized the appointment of Hugues Lecat as censor within its Board of Directors, with immediate effect. This decision foreshadows his potential appointment as director and then President of the company, subject to approval at the next General Meeting.

The arrival of Hugues Lecat is welcomed with enthusiasm by the members of the board and Eric Guerbet, who highlight his significant experience in the pharmaceutical sector and his strategic vision as assets for the future development of the group. Hugues Lecat, whose career has notably evolved at Medtronic France, Aventis Pharma France and Sanofi-Aventis OTC, is ready to support Managing Director David Hale to continue to position Guerbet as a leader in the field of diagnostic and interventional imaging.